Previous close | 0.1900 |
Open | 0.0700 |
Bid | 0.0000 |
Ask | 0.1500 |
Strike | 65.00 |
Expiry date | 2024-07-19 |
Day's range | 0.0700 - 0.1900 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Merck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and the UK, that seeks to treat patients with sight-threatening diseases. Its major drug in clinical stage, Restoret, aims to treat retinal diseases characterized by leakage that can lead to impaired vision.
Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.
RAHWAY, N.J., May 28, 2024--Merck Announces Third-Quarter 2024 Dividend